SAGE has been on its own phase the last 2 trading days. Jan 7 - announced Phase 3 success of SAGE-217 for postpartum depression; same day AXS-05 for MDD was reported.
Both drugs are being compared to each other for the future MDD treatment; promising (as usual). Axsome is a low hanging fruit with a higher volume but I do like how SAGE moves. I'll have to see this through.
Short float is at 7.78%, need more volume.
Word is, there is a "little innovation" nowadays when it comes to CNS disorders like depression, which makes SAGE-217 is worth the watch.
交易結束：目標達成
⋅
評論
⋅
On watch for a sell-off on Feb 19th when they report Q4 earnings. Possible pullback.